For investors

All resources

See below for all resources currently available from Tryp Therapeutics.

Investor resources

Get the latest information for investors.

Download the complete investor pack

Corporate presentation

Read the latest version of our investor deck, which includes information on our progress to date and our upcoming clinical activities.

Download now

Fact sheet

Gain a deeper understanding of our pipeline and products.

Download now

FAQ

Get answers to common questions about Tryp, our clinical trials, commercialization and more.

Download now

Videos

Watch our latest videos for up to date information on our progress.

Bailer, U. F., & Kaye, W. H. (2010). Serotonin: Imaging Findings in Eating Disorders. In (pp. 59-79). Springer Berlin Heidelberg.

Barrett, F. S., Bradstreet, M. P., Leoutsakos, J.-M. S., Johnson, M. W., & Griffiths, R. R. (2016). The Challenging Experience Questionnaire: Characterization of challenging experiences with psilocybin mushrooms. Journal of Psychopharmacology, 30(12), 1279-1295.

Barrett, F. S., Johnson, M. W., & Griffiths, R. R. (2015). Validation of the revised Mystical Experience Questionnaire in experimental sessions with psilocybin. Journal of Psychopharmacology, 29(11), 1182-1190.

Bond, F. W., Hayes, S. C., Baer, R. A., Carpenter, K. M., Guenole, N., Orcutt, H. K., Waltz, T., & Zettle, R. D. (2011). Preliminary psychometric properties of the Acceptance and Action Questionnaire-II: a revised measure of psychological inflexibility and experiential avoidance. Behav Ther, 42(4), 676-688.

Brown, R. T., Nicholas, C. R., Cozzi, N. V., Gassman, M. C., Cooper, K. M., Muller, D., Thomas, C. D., Hetzel, S. J., Henriquez, K. M., Ribaudo, A. S., & Hutson, P. R. (2017). Pharmacokinetics of Escalating Doses of Oral Psilocybin in Healthy Adults. Clin Pharmacokinet, 56(12), 1543-1554.

Buckholtz NS, Zhou DF, Freedman DX, et al. Lysergic acid diethylamide (LSD) administration selectively downregulates serotonin2 receptors in rat brain. Neuropsychopharmacology 1990;3:137–48.

Bull LE, Oliver C, Woodcock KA. Skin Picking in People with Prader-Willi Syndrome: Phenomenology and Management. J Autism Dev Disord. 2021 Jan;51(1):286-297.

Carhart-Harris, R. L., & Nutt, D. J. (2013). Experienced drug users assess the relative harms and benefits of drugs: a web-based survey. J Psychoactive Drugs, 45(4), 322-328.

Carhart-Harris, R. L., Bolstridge, M., Day, C. M., et al. (2018). Psilocybin with psychological support for treatment-resistant depression: six- month follow-up. Psychopharmacology, 235(2), 399-408. doi:10.1007/s00213-017-4771-x

Carhart-Harris, R. L., Leech, R., Hellyer, P. J., Shanahan, M., Feilding, A., Tagliazucchi, E., Chialvo, D. R., & Nutt, D. (2014). The entropic brain: a theory of conscious states informed by neuroimaging research with psychedelic drugs. Frontiers in Human Neuroscience, 8.

Carhart-Harris, R., Giribaldi, B., Watts, R., Nutt, D.J. (2021) Trial of Psilocybin versus Escitalopram for Depression. N Engl J Med., 384:1402-11.

Castellanos JP, Woolley C, Bruno KA, et al. (2020) Chronic pain and psychedelics: a review and proposed mechanism of action. Reg Anesth Pain Med. 45(7):486-494.

Chen, J., Li, M., Yan, X., Wu, E., Zhu, H., Lee, K. J., Chu, V. M., Zhan, L., Lee, W., & Kang, J. S. (2011). Determining the pharmacokinetics of psilocin in rat plasma using ultra-performance liquid chromatography coupled with a photodiode array detector after orally administering an extract of Gymnopilus spectabilis. J Chromatogr B Analyt Technol Biomed Life Sci, 879(25), 2669-2672.

Citrome, L. (2019). Binge eating disorder revisited: what's new, what's different, what's next. CNS Spectr, 24(S1), 4- 13.

Dahmane, E., Hutson, P. R., & Gobburu, J. V. S. (2021). Exposure-Response Analysis to Assess the Concentration- QTc Relationship of Psilocybin/Psilocin. Clin Pharmacol Drug Dev, 10(1), 78-85.

Davis, A. K., Barrett, F. S., May, D. G., Cosimano, M. P., Sepeda, N. D., Johnson, M. W., Finan, P. H., & Griffiths, R. R. (2021). Effects of Psilocybin-Assisted Therapy on Major Depressive Disorder. JAMA Psychiatry, 78(5), 481.

Erritzoe, D., Frokjaer, V. G., Haugbol, S., Marner, L., Svarer, C., Holst, K., Baaré, W. F. C., Rasmussen, P. M., Madsen, J., Paulson, O. B., Knudsen, G. M. (2009) Brain serotonin 2A receptor binding: relations to body mass index, tobacco and alcohol use. Neuroimage, 46(1):23-30.

Espiard, M. L., Lecardeur, L., Abadie, P., Halbecq, I., & Dollfus, S. (2005). Hallucinogen persisting perception disorder after psilocybin consumption: a case study. Eur Psychiatry, 20(5-6), 458-460.

Fairburn, C. G., & Beglin, S. J. (1994). Assessment of eating disorders: interview or self-report questionnaire? Int J Eat Disord, 16(4), 363-370.

Foldi, C. J., Liknaitzky, P., Williams, M., & Oldfield, B. J. (2020). Rethinking Therapeutic Strategies for Anorexia Nervosa: Insights From Psychedelic Medicine and Animal Models. Frontiers in Neuroscience, 14.

Geyer, M. A., & Vollenweider, F. X. (2008). Serotonin research: contributions to understanding psychoses. Trends Pharmacol Sci, 29(9), 445-453.

González-Maeso J, Weisstaub NV, Zhou M, et al. Hallucinogens recruit specific cortical 5-HT2A receptor-mediated signaling pathways to affect behavior. Neuron 2007;53:439–52.

González-Maeso J, Yuen T, Ebersole BJ, et al. Transcriptome fingerprints distinguish hallucinogenic and nonhallucinogenic 5-hydroxytryptamine 2A receptor agonist effects in mouse somatosensory cortex. J Neurosci 2003;23:8836–43

Gormally, J., Black, S., Daston, S., & Rardin, D. (1982). The assessment of binge eating severity among obese persons. Addict Behav, 7(1), 47-55.

Gouzoulis-Mayfrank, E., Thelen, B., Habermeyer, E., Kunert, H. J., Kovar, K. A., Lindenblatt, H., Hermle, L., Spitzer, M., & Sass, H. (1999). Psychopathological, neuroendocrine and autonomic effects of 3,4- methylenedioxyethylamphetamine (MDE), psilocybin and d-methamphetamine in healthy volunteers. Results of an experimental double-blind placebo-controlled study. Psychopharmacology (Berl), 142(1), 41- 50.

Griffiths, R. R., Johnson, M. W., Carducci, M. A., Umbricht, A., Richards, W. A., Richards, B. D., Cosimano, M. P., & Klinedinst, M. A. (2016). Psilocybin produces substantial and sustained decreases in depression and anxiety in patients with life-threatening cancer: A randomized double-blind trial. Journal of Psychopharmacology, 30(12), 1181-1197.

Griffiths, R. R., Johnson, M. W., Richards, W. A., Richards, B. D., McCann, U., & Jesse, R. (2011). Psilocybin occasioned mystical-type experiences: immediate and persisting dose-related effects. Psychopharmacology, 218(4), 649-665.

Griffiths, R. R., Richards, W. A., McCann, U., & Jesse, R. (2006). Psilocybin can occasion mystical-type experiences having substantial and sustained personal meaning and spiritual significance. Psychopharmacology (Berl), 187(3), 268-283; discussion 284-292. Grignaschi, G., Sironi, F., & Samanin, R. (1996). Stimulation of 5-HT2A receptors in the paraventricular hypothalamus attenuates neuropeptide Y-induced hyperphagia through activation of corticotropin releasing factor. Brain Res, 708(1-2), 173-176.

Grob, C. S., Danforth, A. L., Chopra, G. S., et al. (2011). Pilot study of psilocybin treatment for anxiety in patients with advanced-stage cancer. Archives of General Psychiatry, 68(1), 71-78. doi:10.1001/archgenpsychiatry.2010.116

Guerdjikova, A. I., Mori, N., Casuto, L. S., & McElroy, S. L. (2019). Update on Binge Eating Disorder. Med Clin North Am, 103(4), 669-680.

Guy, W. (1976). ECDEU assessment manual for psychopharmacology U.S. Dept. of Health, Education, and Welfare, Public Health Service, Alcohol, Drug Abuse, and Mental Health Administration, National Institute of Mental Health, Psychopharmacology Research Branch, Division of Extramural Research Programs.

Hasler, F., Bourquin, D., Brenneisen, R., Bär, T., & Vollenweider, F. X. (1997). Determination of psilocin and 4- hydroxyindole-3-acetic acid in plasma by HPLC-ECD and pharmacokinetic profiles of oral and intravenous psilocybin in man. Pharm Acta Helv, 72(3), 175-184.

Hasler, F., Grimberg, U., Benz, M. A., Huber, T., & Vollenweider, F. X. (2004). Acute psychological and physiological effects of psilocybin in healthy humans: a double-blind, placebo-controlled dose-effect study. Psychopharmacology (Berl), 172(2), 145-156.

Heinricher MM, Tavares I, Leith JL, et al. Descending control of nociception: specificity, recruitment and plasticity. Brain Res Rev 2009;60:214–25.

Hopf, A., & Eckert, H. (1974). Distribution patterns of 14-C-psilocin in the brains of various animals. Act Nerv Super (Praha), 16(1), 64-66.

Horita, A., & Weber, L. J. (1961). The enzymic dephosphorylation and oxidation of psilocybin and psilocin by mammalian tissue homogenates. Biochem Pharmacol, 7, 47-54.

Houazene, S., Leclerc, J. B., O'Connor, K., & Aardema, F. (2021). "Shame on you": The impact of shame in body- focused repetitive behaviors and binge eating. Behav Res Ther, 138, 103804.

Isbell H, Miner EJ, Logan CR. Cross tolerance between d-2-brom-lysergic acid diethylamide (BOL-148) and the d-diethylamide of lysergic acid (LSD-25). Psychopharmacologia 1959;1:109–16

Johnson MW, Griffiths RR. (2017) Potential Therapeutic Effects of Psilocybin. Neurotherapeutics, 14(3):734- 740. DOI: 10.1007/s13311-017-0542-y Johnson, M. W., Sewell, R. A., & Griffiths, R. R. (2012). Psilocybin dose-dependently causes delayed, transient headaches in healthy volunteers. Drug Alcohol Depend, 123(1 3), 132- 140. doi:10.1016/j.drugalcdep.2011.10.029

Johnson, M., Richards, W., & Griffiths, R. (2008). Human hallucinogen research: guidelines for safety. Journal of Psychopharmacology, 22(6), 603-620.

Kalberer, F., Kreis, W., & Rutschmann, J. (1962). The fate of psilocin in the rat. Biochem Pharmacol, 11, 261-269.

Kayadjanian, N., Vrana-Diaz, C., Bohonowych, J., Strong, T. V., Morin, J., Potvin, D., & Schwartz, L. (2021). Characteristics and relationship between hyperphagia, anxiety, behavioral challenges and caregiver burden in Prader-Willi syndrome. PLoS ONE, 16(3), e0248739.

Kuner R, Flor H. Structural plasticity and reorganisation in chronic pain. Nat Rev Neurosci 2017;18:20–30

Kyzar EJ, Nichols CD, Gainetdinov RR, et al. Psychedelic drugs in biomedicine. Trends Pharmacol Sci 2017;38:992–1005.

Lafrance, A., Loizaga-Velder, A., Fletcher, J., Renelli, M., Files, N., & Tupper, K. W. (2017). Nourishing the Spirit: Exploratory Research on Ayahuasca Experiences along the Continuum of Recovery from Eating Disorders. J Psychoactive Drugs, 49(5), 427-435.

Li C-T, Chen L-F, Tu P-C, et al. Impaired prefronto-thalamic functional connectivity as a key feature of treatment-resistant depression: a combined MEG, PET and rTMS study. PLoS One 2013;8:e70089.

Liu F-Y, Qu X-X, Ding X, et al. Decrease in the descending inhibitory 5-HT system in rats with spinal nerve ligation. Brain Res 2010;1330:45–60. 51

Liu F-Y, Xing G-G, Qu X-X, et al. Roles of 5-hydroxytryptamine (5-HT) receptor subtypes in the inhibitory effects of 5-HT on C-fiber responses of spinal wide dynamic range neurons in rats. J Pharmacol Exp Ther 2007;321:1046–53.

Lutter, M., & Nestler, E. J. (2009). Homeostatic and hedonic signals interact in the regulation of food intake. J Nutr, 139(3), 629-632.

Lyons, T., & Carhart-Harris, R. L. (2018). More Realistic Forecasting of Future Life Events After Psilocybin for Treatment-Resistant Depression. Frontiers in Psychology, 9.

MacIver K, Lloyd DM, Kelly S, et al. Phantom limb pain, cortical reorganization and the therapeutic effect of mental imagery. Brain 2008;131:2181–91. 79

Maclean, K. A., Johnson, M. W., & Griffiths, R. R. (2011). Mystical experiences occasioned by the hallucinogen psilocybin lead to increases in the personality domain of openness. Journal of Psychopharmacology, 25(11), 1453-1461.

Madsen, M. K., Fisher, P. M., Burmester, D., Dyssegaard, A., Stenbæk, D. S., Kristiansen, S., Johansen, S. S., Lehel, S., Linnet, K., Svarer, C., Erritzoe, D., Ozenne, B., & Knudsen, G. M. (2019). Psychedelic effects of psilocybin correlate with serotonin 2A receptor occupancy and plasma psilocin levels. Neuropsychopharmacology, 44(7), 1328-1334.

Metzner, R. (2005). Sacred Mushroom of Vision: Teonanacatl. Park Street Press. Nichols, D. E. (2004). Hallucinogens. Pharmacol Ther, 101(2), 131-181.

Nakae A, Nakai K, Tanaka T, et al. Serotonin2C receptor mRNA editing in neuropathic pain model. Neurosci Res 2008;60:228–31. 52

Nau F, Yu B, Martin D, et al. Serotonin 5-HT2A receptor activation blocks TNF-α mediated inflammation in vivo. PLoS One 2013;8:e75426.

Nicholl BI, Holliday KL, Macfarlane GJ, et al. Association of HTR2A polymorphisms with chronic widespread pain and the extent of musculoskeletal pain: results from two population-based cohorts. Arthritis & Rheumatism 2011;63:810–8

Nichols C, Sanders-Bush E. A single dose of lysergic acid diethylamide influences gene expression patterns within the mammalian brain. Neuropsychopharmacology 2002;26:634–42.

Nichols CD, Garcia EE, Sanders-Bush E. Dynamic changes in prefrontal cortex gene expression following lysergic acid diethylamide administration. Molecular Brain Research 2003;111:182–8.

Nichols CD, Sanders-Bush E. Molecular genetic responses to lysergic acid diethylamide include transcriptional activation of MAP kinase phosphatase-1, C/ EBP-beta and ILAD-1, a novel gene with homology to arrestins. J Neurochem 2004;90:576–84

Nicholson R, Small J, Dixon AK, et al. Serotonin receptor mRNA expression in rat dorsal root ganglion neurons. Neurosci Lett 2003;337:119–22

Nutt, D. J., King, L. A., & Phillips, L. D. (2010). Drug harms in the UK: a multicriteria decision analysis. Lancet, 376(9752), 1558-1565.

Odland AU, Kristensen JL, Andreasen JT (2021) Investigating the role of 5-HT2A and 5-HT2C receptor activation in the effects of psilocybin, DOI, and citalopram on marble burying in mice. Behav Brain Res. ;401:113093.

Otti A, Guendel H, Henningsen P, et al. Functional network connectivity of painrelated resting state networks in somatoform pain disorder: an exploratory fMRI study. Journal of Psychiatry & Neuroscience 2013;38:57–65.

Passie, T., Seifert, J., Schneider, U., & Emrich, H. M. (2002). The pharmacology of psilocybin. Addict Biol, 7(4), 357- 364.

Pei Q, Lewis L, Sprakes ME, et al. Serotonergic regulation of mRNA expression of Arc, an immediate early gene selectively localized at neuronal dendrites. Neuropharmacology 2000;39:463–70

Posner, K., Brown, G. K., Stanley, B., Brent, D. A., Yershova, K. V., Oquendo, M. A., Currier, G. W., Melvin, G. A., Greenhill, L., Shen, S., & Mann, J. J. (2011). The Columbia–Suicide Severity Rating Scale: Initial Validity and Internal Consistency Findings From Three Multisite Studies With Adolescents and Adults. American Journal of Psychiatry, 168(12), 1266-1277.

Ramachandran V, Chunharas C, Marcus Z et al. (2018). Relief from intractable phantom pain by combining psilocybin and mirror visual-feedback (MVF). Neurocase, 24(2), 105-110. doi.org/10.1080/13554794.2018.1468469

Renelli, M., Fletcher, J., Tupper, K. W., Files, N., Loizaga-Velder, A., & Lafrance, A. (2020). An exploratory study of experiences with conventional eating disorder treatment and ceremonial ayahuasca for the healing of eating disorders. Eat Weight Disord, 25(2), 437-444.

Romeo B, Hermand M, Pétillion A, Karila L, Benyamina A.J (2021) Clinical and biological predictors of psychedelic response in the treatment of psychiatric and addictive disorders: A systematic review. Psychiatr Res. 137:273-282.

Roseman, L., Haijen, E., Idialu-Ikato, K., Kaelen, M., Watts, R., & Carhart-Harris, R. (2019). Emotional breakthrough and psychedelics: Validation of the Emotional Breakthrough Inventory. J Psychopharmacol, 33(9), 1076- 1087.

Ross, S., Bossis, A., Guss, J., Agin-Liebes, G., Malone, T., Cohen, B., Mennenga, S. E., Belser, A., Kalliontzi, K., Babb, J., Su, Z., Corby, P., & Schmidt, B. L. (2016). Rapid and sustained symptom reduction following psilocybin treatment for anxiety and depression in patients with life-threatening cancer: a randomized controlled trial. Journal of Psychopharmacology, 30(12), 1165-1180.

Rucker, J. J. H., Iliff, J., & Nutt, D. J. (2018). Psychiatry & the psychedelic drugs. Past, present & future. Neuropharmacology, 142, 200-218. https://doi.org/10.1016/j.neuropharm.2017.12.040

Samodien, E., & Chellan, N. (2021). Hypothalamic neurogenesis and its implications for obesity-induced anxiety disorders. Front Neuroendocrinol, 60, 100871.

Schindler EA, Gottschalk CH, Weil MJ, et al. (2015). Indoleamine hallucinogens in cluster headache: Results of the clusterbusters medication use survey. J Psychoactive Drugs, 47(5):372-381.

Serretti, A., Drago, A., & De Ronchi, D. (2007). HTR2A gene variants and psychiatric disorders: a review of current literature and selection of SNPs for future studies. Curr Med Chem, 14(19), 2053-2069.

Spriggs, M. J., Kettner, H., & Carhart-Harris, R. L. (2021). Positive effects of psychedelics on depression and wellbeing scores in individuals reporting an eating disorder. Eat Weight Disord, 26(4), 1265-1270.

Stahl S, Briley M. Understanding pain in depression. Hum Psychopharmacol 2004;19:S9–13 Studerus, E., Kometer, M., Hasler, F., & Vollenweider, F. X. (2011). Acute, subacute and long-term subjective effects of psilocybin in healthy humans: a pooled analysis of experimental studies. J Psychopharmacol, 25(11), 1434-1452.

Sugimoto, Y., Yoshikawa, T., Noma, T., & Yamada, J. (2001). The 5-HT2C/2B Receptor Agonist m- Chlorophenylpiperazine (mCPP) Inhibits 2-Deoxy-D-glucose (2-DG)-Induced Hyperphagia in Rats. Biological and Pharmaceutical Bulletin, 24(12), 1431-1433.

Thorp SL, Suchy T, Vadivelu N, et al. Functional connectivity alterations: novel therapy and future implications in chronic pain management. Pain Physician 2018;21:E207–14

Tylš, F., Páleníček, T., & Horáček, J. (2014). Psilocybin--summary of knowledge and new perspectives. Eur Neuropsychopharmacol, 24(3), 342-356.

Vaidya VA, Marek GJ, Aghajanian GK, et al. 5-Ht2A receptor-mediated regulation of brain-derived neurotrophic factor mRNA in the hippocampus and the neocortex. J Neurosci 1997;17:2785–95

Van Steenwinckel J, Brisorgueil M-J, Fischer J, et al. Role of spinal serotonin 5-HT2A receptor in 2’,3’-dideoxycytidine-induced neuropathic pain in the rat and the mouse. Pain 2008;137:66–80.

Villemure C, Bushnell MC. Mood influences supraspinal pain processing separately from attention. J Neurosci 2009;29:705–15

Vlaardingerbroek, H., Van Den Akker, E. L. T., & Hokken-Koelega, A. C. S. (2021). Appetite- and weight-inducing and inhibiting neuroendocrine factors in Prader–Willi syndrome, Bardet–Biedl syndrome and craniopharyngioma versus anorexia nervosa. Endocrine Connections, 10(5), R175-R188.

Wei H, Chen Y, Hong Y. The contribution of peripheral 5-hydroxytryptamine2A receptor to carrageenan-evoked hyperalgesia, inflammation and spinal Fos protein expression in the rat. Neuroscience 2005;132:1073–82

Yu B, Becnel J, Zerfaoui M, et al. Serotonin 5-hydroxytryptamine(2A) receptor activation suppresses tumor necrosis factor-alpha-induced inflammation with extraordinary potency. J Pharmacol Exp Ther 2008;327:316–23.

Zigmond, A. S., & Snaith, R. P. (1983). The hospital anxiety and depression scale. Acta Psychiatr Scand, 67(6), 361- 370.